



# City of Flint, Michigan

Third Floor, City Hall  
1101 S. Saginaw Street  
Flint, Michigan 48502  
[www.cityofflint.com](http://www.cityofflint.com)

**Meeting Agenda – FINAL**  
**Wednesday, September 3, 2025**  
**5:00 PM**

**City Council Chambers**

## **GOVERNMENTAL OPERATIONS COMMITTEE**

**VACANT, Chairperson**

**Leon El-Alamin, Ward 1**

**Ladel Lewis, Ward 2**

**LaShawn Johnson, Ward 3**

**Judy Priestley, Ward 4**

**Jerri Winfrey-Carter, Ward 5**

**Tonya Burns, Ward 6**

**Candice Mushatt, Ward 7**

**Dennis Pfeiffer, Ward 8**

**Jonathan Jarrett, Ward 9**

**Davina Donahue, City Clerk**

\*\*\*\*\*

### **ROLL CALL**

### **READING OF DISORDERLY PERSONS CITY CODE SUBSECTION**

*Any person that persists in disrupting this meeting will be in violation of Flint City Code Section 31-10, Disorderly Conduct, Assault and Battery, and Disorderly Persons, and will be subject to arrest for a misdemeanor. Any person who prevents the peaceful and orderly conduct of any meeting will be given one warning. If they persist in disrupting the meeting, that individual will be subject to arrest. Violators will be removed from the meetings.*

### **REQUEST FOR AGENDA CHANGES/ADDITIONS**

### **PUBLIC COMMENT**

*Members of the public who wish to address the City Council or its committees must register before the meeting begins. A box will be placed at the entrance to the Council Chambers for collection of registrations. No additional speakers or slips will be accepted after the meeting begins.*

*Members of the public shall have no more than three (3) minutes per speaker during public comment, with only one speaking opportunity per speaker.*

## **COUNCIL RESPONSE**

*Councilmembers may respond once to all public speakers only after all public speakers have spoken. An individual Councilmember's response shall be limited to two (2) minutes.*

## **CONSENT AGENDA**

*Per the amended Rules Governing Meetings of the Flint City Council (as adopted by the City Council on Monday, April 22, 2024), the Chair may request the adoption of a "Consent Agenda". After a motion to adopt a Consent Agenda is made and seconded, the Chair shall ask for separations. Any agenda item on a Consent Agenda shall be separated at the request of any Councilmember. After any separations, there is no debate on approving the Consent Agenda – it shall be voted on or adopted without objection.*

## **RESOLUTIONS**

**250285-T** Request for Voluntary Suspension/Flint City Council Official Duties/1<sup>st</sup> Ward Councilman Leon El-Alamin

Resolution resolving that the Flint City Council calls upon Councilman Leon El-Alamin to voluntarily suspend his official duties, including attending Council and committee meetings in a voting capacity, introducing legislation, presiding over any committee roles, and representing the City in an official capacity, until the criminal case identified above is resolved by dismissal, plea, or final adjudication, AND, further resolving that, during this voluntary suspension, the Council requests that Councilman El-Alamin abstain from all votes and refrain from participating in Council deliberations, except to the limited extent required by law to preserve his rights, AND, further resolving that Council affirms its commitment to due process and the presumption of innocence in criminal proceedings, while also affirming the City's compelling interest in protecting survivors, deterring violence, and maintaining public confidence

in municipal governance, AND, finally resolving that nothing in this Resolution shall be construed to limit any rights, remedies, or Charter processes that may arise should statutory or Charter-specified disqualifications occur, including – but not limited to – resignation or vacancy upon conviction.

## **APPOINTMENTS**

**250133-T** Appointment/Hurley Board of Hospital Managers/Dr. Khalid M. Ahmed

Resolution resolving that the Flint City Council approves the appointment of Dr. Khalid M. Ahmed (Flint, Michigan, 48503) to serve a five-year term on the Hurley Board of Hospital Managers, with such term commencing immediately and expiring April 30, 2030.

## **SPECIAL ORDERS/DISCUSSION ITEMS**

**250286-T** A Discussion Item to allow the City Council to talk through meeting accommodations for individuals with disabilities and discuss the ways that the body would like to approach and effectuate said accommodations.

## **ADJOURNMENT**

250285-T

RESOLUTION: \_\_\_\_\_

PRESENTED: 9-3-2025

ADOPTED: \_\_\_\_\_

**RESOLUTION CALLING FOR COUNCILMAN LEON EL-ALAMIN TO VOLUNTARILY  
SUSPEND HIS DUTIES PENDING RESOLUTION OF HIS CRIMINAL CASE**

**BY THE CITY COUNCIL:**

**WHEREAS**, members of the Flint City Council are elected to serve the public interest and uphold the public trust, acting at all times in a manner that reflects integrity, accountability, and respect for the safety and dignity of Flint residents; and

**WHEREAS**, Councilman Leon El-Alamin has been charged in Genesee County with offenses reportedly including *assault with intent to do great bodily harm less than murder* (felony) and *domestic violence* (misdemeanor) (Case/Docket No. 2025-25T01998-FY; alleged incident date 7/10/2025); and

**WHEREAS**, under the Flint City Charter, Council lacks the authority to unilaterally remove or suspend an elected member based solely on allegations or pending charges; vacancies occur only upon conviction, resignation, or similar disqualification; nonetheless, Council possesses the authority to express moral and political stances through resolutions; and

**WHEREAS**, domestic and intimate-partner violence are urgent public-safety and public-health issues in our community, and survivors deserve to see their city's leadership stand unequivocally against violence and for due process, safety, and accountability; and

**WHEREAS**, in order to protect the integrity of Council deliberations, avoid distractions from City business, and maintain public confidence during the pendency of the criminal process, it is prudent and appropriate to request a voluntary, temporary suspension of duties by the member charged; now, therefore,

**BE IT RESOLVED**, that the Flint City Council hereby calls upon Councilman Leon El-Alamin to voluntarily suspend his official duties including attending Council and committee meetings in a voting capacity, introducing legislation, presiding over any committee roles, and representing the City in an official capacity until the criminal case identified above is resolved by dismissal, plea, or final adjudication; and

**BE IT FURTHER RESOLVED**, that during this voluntary suspension the Council requests that Councilman El-Alamin abstain from all votes and refrain from participating in Council deliberations, except to the limited extent required by law to preserve his rights; and

**BE IT FURTHER RESOLVED**, that Council affirms its commitment to due process and the presumption of innocence in criminal proceedings while also affirming the City's compelling interest in protecting survivors, deterring violence, and maintaining public confidence in municipal governance; and

**BE IT FINALLY RESOLVED**, that nothing in this Resolution shall be construed to limit any rights, remedies, or charter processes that may arise should statutory or Charter-specified disqualifications occur, including but not limited to resignation or vacancy upon conviction.

**APPROVED AS TO FORM:**

**APPROVED BY CITY COUNCIL:**

---

**JoAnne Gurley, Chief Legal Officer**



250133-T

RESOLUTION NO.: \_\_\_\_\_

PRESENTED: 4-23-2025

ADOPTED: \_\_\_\_\_

**RESOLUTION APPROVING THE APPOINTMENT OF DR. KHALID M. AHMED TO THE HURLEY BOARD OF HOSPITAL MANAGERS.**

Section 6-201(A) of the Flint City Charter provides that members of the Board of Hospital Managers shall "consist of fifteen (15) members appointed by the mayor with the approval of the City Council."

Pursuant to that authority, Mayor Sheldon A. Neeley appoints Dr. Khalid M. Ahmed of Flint, MI 48503, to the Board of Hospital Managers, to replace Phillip W. Shatz whose term expired April 30, 2023

**BE IT RESOLVED** that the Flint City Council approves the appointment of Dr. Khalid M. Ahmed (Flint MI 48503) to serve a five-year term on the Hurley Board of Hospital Managers, with each term commencing immediately and expiring on April 30, 2030.


**FOR THE CITY OF FLINT:**

**APPROVED BY CITY COUNCIL:**

  
Cyndee Edwards, City Administrator

\_\_\_\_\_

**APPROVED AS TO FORM:**

  
Joanne Garvey, City Attorney

---

# **KHALID M. AHMED, M.D**

---

2700 Robert T-longway Blvd. Suite B, Flint, MI 48503 ♦ P. 810-235-2004 ♦ F.810-235-2841 ♦ [kahmed2700@gmail.com](mailto:kahmed2700@gmail.com)

---

## **EDUCATION**

---

- 2006** American Board of Internal Medicine
- 1992** Royal College of Physicians of Ireland
- 1981** M.B.B.S., Faculty of Medicine University of Khartoum,  
Khartoum, Sudan

---

## **CURRENT POSITIONS**

---

- 2021 - Present** Chief of Staff, Hurley Medical Center, Flint, MI
- 2021 - 2022** President, Genesee County Medical Society
- 2018 - Present** Board member, Genesee County Medical Society
- 2018 - Present** Board member, Islamic Medical Association of Mid-Michigan
- 2012 - 2016** Board member, Genesee Academy School
- 2014 - Present** Clinical Director, Internal Medicine, Hurley Medical Center. Flint, MI
- 2013 - 2021** Chairman, Department of Medicine, Hurley Medical Center, Flint, MI.
- 2010 - 2019** Vice Chief of Staff, Interim Chief of staff, Hurley Medical Center, Flint, MI
- 1996 - Present** Attending & Consultant Physician, Department of Internal Medicine. Hurley Medical Center and Michigan Health Specialists, Flint, MI
- 1996 - Present** Associate Professor of Internal Medicine, Michigan State University, College of Human Medicine, Flint, MI.
- 1996 - Present** Internal Medicine Physician, Flint, MI

---

## **AWARDS**

---

- Pinnacle Award, Hurley Medical Center, 2013
- Physician of the Year, Arab American Heritage Council, 2019

---

## ORGANIZATION

---

Active Member of the African American Physicians Association.  
Active Member of the Genesee County Medical Society.  
Active Member of the Michigan State Medical Society.  
Active Member of the American Medical Association.  
Active Member of the American College of Physicians

---

## AFFILIATION WITH RESEARCH CENTER

---

2015-Present    Principal investigator, Flint Clinical Research PLLC, Flint, MI  
2015-Present    Sub-investigator, Elite Research Center, Flint, MI

---

## CLINICAL RESEARCH EXPERIENCE AND PUBLICATIONS

---

- A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease(CULTIVATE ). 2020
- A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain (CAPTIVATE). 2019
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis (ELEVATE). 2019
- A randomized, double blind controlled factorial clinical trial of edetate disodium-based chelation and high dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction. 2018
- A randomized, Parallel -group , Placebo-Controlled, clinical endpoint bioequivalence study of generic Fluticasone Propionate 100 ug and Salmeterol Xinafoate 50 ug inhalation powder compared with Advair DiskusR 100/50 in subjects with Asthma. 2018
- A randomized, double blind controlled factorial clinical trial of Edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction. 2018
- A Phase IV, 12-week, randomized, double-blind, triple dummy study to compare single inhaler triple therapy, Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) with multiple inhaler therapy (Budesonide/Formoterol plus Tiotropium) based on lung function and symptoms in participants with chronic obstructive pulmonary disease. 2018



- A Phase 3, multi-center, multi-national, placebo controlled, randomized, double-blind 26-week study to assess the safety and efficacy of CaPre® in patients with severe hypertriglyceridemia. 2018
- Inflammatory Bowel Disease registry. Corrona. 2017
- A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia (EMPHENE). 2017
- A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome. 2017
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients with Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease, VK2809-201. 2017
- A double-blind, randomized, placebo-controlled, parallel-group, phase IV study to evaluate to effect of Acridinium Bromide on long-term cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD (ASCENT COPD). 2016
- A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5 mg Co – administered with Dapagliflozin 5 mg compared to Saxagliptin 5 mg or Dapagliflozin 5 mg all given as add –on therapy to metformin in Patients with Type 2 Diabetes who have inadequate Glycemic Control on Metformin Alone. 2016
- A phase 2 Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Gemcabene in Patients with Severe Hypertriglyceridemia (INDIGO-1). 2016
- A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of Roxadustat (FG-4592) for the treatment of anemia in chronic kidney disease patients not on dialysis. 2015
- An open label, long-term study to assess the immunogenicity of Linacotide administered orally to adult patients with irritable bowel syndrome with constipation or chronic idiopathic constipation. 2015
- Ahmed K., Managing Malnutrition in Inflammatory Bowel Disease, Hospital Physicians. Vol 30 12:13-17 1994
- Ahmed K., Saeed E. Nephrotic Syndrome and Pulmonary Artery Thrombosis, case report, American Journal of Nephrology. 1995; 15:181-185
- Ahmed K., Jackson L. Heparin Use In Right Arterial Thrombosis, Oral Presentation ACP Michigan Chapter Annual Meeting, Traverse City 1995
- Ahmed K. , Chan S. Mixed Lineage Hematologic Malignancy (Mycloblastic and T Lymphoblastic), Abstract, Blood Vol 86 No. 10 Supp. Nov. 1995
- Ahmed K. , Issawi I. Use of Flecainide for Refractory Arterial Tachycardia of Pregnancy, A case report, Manuscript Accepted for Publication, American Journal of Critical Care.
- Ahmed K., Filos O., Rapid Infusion of Magnesium Sulfate In Severe Acute Asthma, Case Series, Oral Presentation, ACP Michigan Chapter Conference, Sept. 1995
- Ahmed K., Seedahmed E . Holt-Oram Syndrome. Cases Presentations Community Wide Research Forum, April 2005. Flint, Michigan.